Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?-Reference-Cited by-同舟云学术

Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?

Published:2021-08 Issue: Volume: Page:
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Kjoe Philippe R. Lee Meeuw^ORCID,van der Wall Elsken,Schagen Sanne B.

Funder

KWF Kankerbestrijding

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference78 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Mechanisms of endocrine resistance in breast cancer;Osborne;Annu Rev Med,2011

3. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer;Wefel;Cancer,2010

4. Genetic modulation of neurocognitive development in cancer patients throughout the lifespan: a systematic review;Sleurs;Neuropsychol Rev,2019

5. Neurotoxic effects of anthracycline-vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors;Kesler;JAMA Oncol,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS);Expert Opinion on Drug Safety;2024-08-05

2. Neuropsychological Evaluation for Oncology;Neurologic Clinics;2024-06

3. Synthesis, characterization, biological evaluation and in silico studies of novel 1,3,4-thiadiazole derivatives as aromatase inhibitors;Journal of Molecular Structure;2024-01

4. Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database;Frontiers in Pharmacology;2023-10-20

5. Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management;BMJ;2023-03-15